PMID- 33763725
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20211015
IS  - 1433-7339 (Electronic)
IS  - 0941-4355 (Linking)
VI  - 29
IP  - 11
DP  - 2021 Nov
TI  - Latent infection screening and prevalence in cancer patients born outside of 
      Australia: a universal versus risk-based approach?
PG  - 6193-6200
LID - 10.1007/s00520-021-06116-w [doi]
AB  - PURPOSE: Contention surrounds how best to screen patients for latent and 
      undiagnosed infection prior to cancer treatment. Early treatment and prophylaxis 
      against reactivation may improve infection-associated morbidity. This study 
      sought to examine rates of screening and prevalence of latent infection in 
      overseas-born patients receiving cancer therapies. METHODS: A single-centre 
      retrospective audit of 952 overseas-born patients receiving chemotherapy, 
      targeted agents and immunotherapy between January 1 and December 31 2019 was 
      undertaken at Peter MacCallum Cancer Centre. Pre-treatment screening for 
      hepatitis B (HBV), hepatitis C (HCV), human immunodeficiency virus (HIV), latent 
      tuberculosis (LTBI), toxoplasmosis and strongyloidiasis was audited. RESULTS: 
      Approximately half of our overseas-born patients were screened for HBV (58.9%) 
      and HCV (50.7%). Fewer patients were screened for HIV (30.5%), LTBI (18.3%), 
      strongyloidiasis (8.6%) or toxoplasmosis (8.1%). Although 59.7% of our patients 
      were born in countries with high epidemiological risk for latent infection, 
      according to World Health Organization data, 35% were not screened for any 
      infection prior to commencement of therapy. CONCLUSION: The prevalence of latent 
      infections amongst overseas-born patients with cancer, and complexities 
      associated with risk-based screening, likely supports universal latent infection 
      screening amongst this higher-risk cohort.
CI  - (c) 2021. Crown.
FAU - Reynolds, Gemma
AU  - Reynolds G
AUID- ORCID: 0000-0002-9561-3592
AD  - Department of Infectious Diseases, Peter MacCallum Cancer Centre, 305 Grattan 
      Street, Melbourne, Victoria, 3000, Australia. gemma.reynolds@petermac.org.
FAU - Haeusler, Gabrielle
AU  - Haeusler G
AD  - Department of Infectious Diseases, Peter MacCallum Cancer Centre, 305 Grattan 
      Street, Melbourne, Victoria, 3000, Australia.
AD  - Department of Infectious Diseases, Royal Children's Hospital, Melbourne, 
      Victoria, Australia.
AD  - National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, 
      Melbourne, Victoria, Australia.
AD  - Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, 
      Victoria, Australia.
AD  - Murdoch Children's Research Institute, Parkville, Victoria, Australia.
FAU - Slavin, Monica A
AU  - Slavin MA
AD  - Department of Infectious Diseases, Peter MacCallum Cancer Centre, 305 Grattan 
      Street, Melbourne, Victoria, 3000, Australia.
AD  - National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, 
      Melbourne, Victoria, Australia.
AD  - Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, 
      Victoria, Australia.
FAU - Teh, Benjamin
AU  - Teh B
AD  - Department of Infectious Diseases, Peter MacCallum Cancer Centre, 305 Grattan 
      Street, Melbourne, Victoria, 3000, Australia.
AD  - National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, 
      Melbourne, Victoria, Australia.
AD  - Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, 
      Victoria, Australia.
FAU - Thursky, Karin
AU  - Thursky K
AD  - Department of Infectious Diseases, Peter MacCallum Cancer Centre, 305 Grattan 
      Street, Melbourne, Victoria, 3000, Australia.
AD  - National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, 
      Melbourne, Victoria, Australia.
AD  - Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, 
      Victoria, Australia.
LA  - eng
PT  - Journal Article
DEP - 20210324
PL  - Germany
TA  - Support Care Cancer
JT  - Supportive care in cancer : official journal of the Multinational Association of 
      Supportive Care in Cancer
JID - 9302957
SB  - IM
MH  - Australia/epidemiology
MH  - Early Detection of Cancer
MH  - *Hepatitis B
MH  - Humans
MH  - *Latent Infection
MH  - Mass Screening
MH  - *Neoplasms/drug therapy/epidemiology
MH  - Prevalence
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Cancer therapies
OT  - Latent infections
OT  - Migrant
OT  - Screening
OT  - Universal screening
EDAT- 2021/03/26 06:00
MHDA- 2021/10/16 06:00
CRDT- 2021/03/25 06:37
PHST- 2020/12/01 00:00 [received]
PHST- 2021/02/26 00:00 [accepted]
PHST- 2021/03/26 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
PHST- 2021/03/25 06:37 [entrez]
AID - 10.1007/s00520-021-06116-w [pii]
AID - 10.1007/s00520-021-06116-w [doi]
PST - ppublish
SO  - Support Care Cancer. 2021 Nov;29(11):6193-6200. doi: 10.1007/s00520-021-06116-w. 
      Epub 2021 Mar 24.